Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/18/2011

etreleptin for the treatment of obesity to investigate an antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity. The Company, with partner Takeda Pharmaceutical Company Limited, is committed to working closely with clinical investigators, regulators and outside experts to determine the best path forward.

"We are pleased with the CHMP's recent recommendation to approve BYDUREON in Europe. This therapy could offer millions of people living with diabetes the benefits of a GLP-1 receptor agonist in just one dose per week," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "In the coming quarters, we will continue to advance other key development programs to address the needs of the patients we serve. This includes submitting our reply to the BYDUREON complete response letter, as well as completing our regulatory application for the use of metreleptin in patients with lipodystrophy."

Financial ResultsNet product sales of $150.8 million for the quarter ended March 31, 2011 include net sales of $128.0 million for BYETTA and $22.8 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $172.3 million, consisting of $149.8 million for BYETTA and $22.5 million for SYMLIN for the same period in 2010.

Revenues under collaborative agreements were $1.9 million for the quarter ended March 31, 2011, unchanged from the same period in 2010, and consist of the amortization of upfront fees received under the Company's collaboration agreement with Takeda.  

Selling, general and administrative expenses decreased to $64.6 million for the quarter ended March 31, 2011 from $73.3 million for the same period in 2010. The decrease reflects reduced expenses associated with BYDUREON pre-launch activities and lower business infrastructure spending resulting from continued efforts to
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
3. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
4. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
5. Amylin Pharmaceuticals Reports 2010 Financial Results
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
11. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud Pharmaceuticals, ... design and development, partnering is an integral part ... to design new drugs and identify early stage, ... to further their development. The company also partners ... support this business model, Cloud Pharmaceuticals will be ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Mass. and SYDNEY, Dec. 2, 2010 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... & Obesity Conference on Tuesday, December 7, 2010 at ...
... Dec. 2, 2010 Sagent Pharmaceuticals, Inc., a ... approval and launch of its topotecan hydrochloride for ... innovator,s patent expiry.  Sagent,s topotecan is available in ... latest product to feature Sagent,s proprietary PreventIV Measures™ ...
Cached Medicine Technology:HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection 2
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... September 21, 2014 Recently, iFitDress.com, a well-known ... of beautiful party dresses . In addition, the company ... main aim of the promotion is to benefit all of ... in its online store now. , Along with beautiful ... graceful items. It has recently released its new sexy short ...
(Date:9/20/2014)... September 21, 2014 Weight Destroyer ... by fitness expert Michael Wren that has already helped ... and reverse health conditions like high blood pressure, high ... Shane Michaels, prompting an investigative review. , “Weight ... tips upside down by showing people what is truly ...
(Date:9/20/2014)... Mexico (PRWEB) September 20, 2014 The ... including Villa del Palmar Cabo San Lucas, Villa La ... relation to Hurricane Odile, with plans to welcome guests ... , As of Sept. 19, all members and guests ... home, thanks to a coordinated effort with government authorities. ...
(Date:9/20/2014)... Ticket Down is a dependable source ... popular ticket exchange is offering their customer appreciation promo code ... of tours is beginning to fill up. Many of the ... hit the road, including 21-year-old pop superstar, Ariana Grande. Grande, ... which will take her to 25 cities across the United ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3
... Plavix trial shows double dosage best for angioplasty ... they digest the latest news on what dose of ... are looking at the next generation of clot-busters that ... buzz among cardiologists at last week,s Transcatheter Cardiovascular Therapeutics ...
... Communication woes still plague medical system, researchers find ... an advanced, computerized medical-record system with alerts cannot ... when imaging tests turn up signs of trouble, ... that an electronic medical record that facilitates transmission ...
... but any amount helps, experts say , MONDAY, Sept. 28 ... obese may triple the chances of eliminating their sleep problems ... 10 percent of their body weight was enough to bring ... the Center for Obesity Research and Education at Temple University ...
... Neurology suggests that impaired kidney function is a ... The study, conducted by researchers at Rush University Medical ... cognition related to memory functions. Damage to one of ... associated emotions and other contextual knowledge, is often the earliest ...
... ANN ARBOR, Mich.---The Great Depression had a silver lining: During ... years, according to a University of Michigan study published in ... Academy of Sciences . Life expectancy rose from 57.1 ... analysis by ,U-M researchers Jos A. Tapia Granados and Ana ...
... Mich. (Sept. 28, 2009) Van Andel Research ... ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease ... United States, and that sometimes results in acute myeloid leukemia. ... the disease,s progression and could prove to be a therapeutic ...
Cached Medicine News:Health News:Clot-Busting Therapy Under Review 2Health News:Clot-Busting Therapy Under Review 3Health News:Docs Miss Test Results -- Even With Alerts 2Health News:When Pounds Go, Sleep Apnea May Improve 2Health News:When Pounds Go, Sleep Apnea May Improve 3Health News:Impaired kidney function linked to cognitive decline in elderly 2Health News:U-M study: Life and death during the Great Depression 2Health News:U-M study: Life and death during the Great Depression 3Health News:Van Andel Institute researchers find gene that could lead to new therapies for bone marrow disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: